开发具有选择性高亲和力IL-2R的IL-2的突变体通常需要减少IL-2与CD122或者CD25的相互作用。包括四类:IL-2 muteins,PEGylated IL-2,IL-2-anti-IL-2 免疫复合体和IL-2-CD25融合蛋白。 ▌IL-2 muteins a)对二聚体IL-2R具有选择性的IL-2突变体:IL-2突变...
开发具有选择性高亲和力IL-2R的IL-2的突变体通常需要减少IL-2与CD122或者CD25的相互作用。包括四类:IL-2 muteins,PEGylated IL-2,IL-2-anti-IL-2 免疫复合体和IL-2-CD25融合蛋白。 ▌IL-2 muteins a)对二聚体IL-2R具有选择性的IL-2突变体:IL-2突变蛋白发展之初是为了减少高剂量IL-2对于癌症患者的...
开发具有选择性高亲和力IL-2R的IL-2的突变体通常需要减少IL-2与CD122或者CD25的相互作用。包括四类:IL-2 muteins,PEGylated IL-2,IL-2-anti-IL-2 免疫复合体和IL-2-CD25融合蛋白。 ▌IL-2 muteins a)对二聚体IL-2R具有选择性的IL-2突变体:IL-2突变蛋白发展之初是为了减少高剂量IL-2对于癌症患者的...
The present disclosures related to human interleukin-2 (hIL2) muteins, pharmaceutical formulations thereof, methods for preparing interleukin-2 muteins, recombinant vectors and cells comprising nucleic acids encoding IL2 muteins and methods for the treatment of human disease.Jan Emmerich...
IL2 MUTEINSThe present disclosures is related to IL2 muteins and their uses in the treatment of human disease.EMMERICH, JANKAUDER, STEVEMCCAULEY, SCOTT ALAN
The present disclosures related to human interleukin-2 (hIL2) muteins, pharmaceutical formulations thereof, methods for preparing interleukin-2 muteins, recombinant vectors and cells comprising nucleic acids encoding IL2 muteins and methods for the treatment of human disease....
Using a combination of computational and experimental biology approaches we predicted and developed two novel IL2 muteins with therapeutic potential. The first, designated no-alpha mutein , is an agonist of IL2R signaling with a reduced ability to expand Treg in vivo . In mice, the no-alpha ...
The present disclosures related to human interleukin-2 (hIL2) muteins, pharmaceutical formulations thereof, methods for preparing interleukin-2 muteins, recombinant vectors and cells comprising nucleic acids encoding IL2 muteins and methods for the treatment of human disease.EMMERICH, JAN...
The present disclosures related to human interleukin-2 (hIL2) muteins, pharmaceutical formulations thereof, methods for preparing interleukin-2 muteins, recombinant vectors and cells comprising nucleic acids encoding IL2 muteins and methods for the treatment of human disease.JAN EMMERICH...
The present disclosures related to human interleukin-2 (hIL2) muteins, pharmaceutical formulations thereof, methods for preparing interleukin-2 muteins, recombinant vectors and cells comprising nucleic acids encoding IL2 muteins and methods for the treatment of human disease.EMMERICH, JAN...